Saint Louis University Vaccine Center Recruits Healthy Participants for Flu Human Challenge Study
ST. LOUIS – Researchers at the Saint Louis University Center for Vaccine Development are recruiting people in the St. Louis area to participate in a clinical trial to study healthy adults’ pre-existing immunity to the flu.
Study participants will be infected with the influenza A H3N2 virus while under the care of a medical team in order to learn more about how healthy people’s immune systems respond to an influenza infection.
Daniel Hoft, M.D., Ph.D., director of SLU’s Vaccine Center and principal investigator of the study
Human challenge studies – so named because they “challenge” the human immune system with exposure to a pathogen – allow researchers to study how the immune system fights off illnesses.
“By the time we are adults, we have been infected with the flu many times,” said Daniel Hoft, M.D., Ph.D., director of SLU’s Vaccine Center and principal investigator of the study. “While we have learned a lot about how the flu infects people, it is hard to know exactly when someone is exposed to the flu, and what happens early on after they are exposed to the flu but before they become sick.
“Flu ‘challenge’ studies, where we give a strain of the flu virus to a participant, allow us to follow people closely before and after infection. We learn about the flu virus and the body’s reaction to it. This study may help us to design better flu vaccines or better drugs to treat the flu.”
Saint Louis University is the only study site for the Phase 1 trial.
Researchers will enroll 12 participants in good health who are between the ages of 18 and 45 years old. Participants must live within 60 miles of St. Louis and should not have received a vaccine within 30 days of enrolling in the study.
Following screening visits, participants will stay at the Extended Stay Research Unit (ESRU), located at Saint Louis University’s Salus Center, for at least 10 days. Participants must agree to remain in the ESRU until they are discharged and will not be able to have visitors during that time.
Participants will be given the flu virus through a nasal spray. Researchers will test participants’ antibodies before and after receiving the flu nasal spray to see if having antibodies can protect from flu infection or lead to a milder illness and to better understand how and when the body’s immune response to the flu occurs.
Those enrolled in the study will be compensated for their time and participation up to $3,425 for all completed study visits and phone calls.
Interested participants should contact the Saint Louis University Center for Vaccine Development at:
- Email: vaccine@slu.edu
- Telephone: 314-977-6333
The clinical trial is funded by Saint Louis University’s Stephen C. Peiper and Zi-Xuan Wang Institute for Vaccine Science and Policy.
Saint Louis University Center for Vaccine Development
Saint Louis University has been on the front lines in the fight against pandemics and global health crises for more than three decades and first received federal funding for vaccine research in 1989.
Led by Daniel Hoft M.D., Ph.D., SLU's Center for Vaccine Development is one of only 10 institutions selected by the National Institutes of Health as a Vaccine and Treatment Evaluation Unit (VTEU).
As a VTEU, the Center helps develop and evaluate vaccines that will protect people from infectious diseases and emerging threats. It conducts Phase 1 through 4 vaccine and treatment trials, including clinical studies in collaboration with industry partners.
Stephen C. Peiper and Zi-Xuan Wang Institute for Vaccine Science and Policy
The Stephen C. Peiper and Zi-Xuan Wang Institute for Vaccine Science and Policy was launched in 2020 at Saint Louis University following a generous investment from SLU School of Medicine alumnus Stephen C. Peiper, M.D. and Zi-Xuan “Zoe” Wang, Ph.D. to establish a center of excellence at the intersection of basic and clinical vaccinology, public health, bioethics, law and health equity.
The Institute supports SLU researchers with extensive experience developing vaccines and treatments for infectious diseases who have been on the forefront of protecting the public from pandemics, bioterrorism and other emergent threats.
Saint Louis University School of Medicine
Established in 1836, Saint Louis University School of Medicine has the distinction of awarding the first medical degree west of the Mississippi River. The school educates physicians and biomedical scientists, conducts medical research, and provides health care on a local, national and international level. Research at the school seeks new cures and treatments in five key areas: infectious disease, liver disease, cancer, heart/lung disease, and aging and brain disorders.
Latest Newslink
- Tickets to See Jhumpa Lahiri Receive 2026 St. Louis Literary Award Go on Sale January 23Tickets for the St. Louis Literary Award ceremony honoring Pulitzer Prize-winning author Jhumpa Lahiri will go on sale Friday, Jan. 23, at 10 a.m. Lahiri will receive the award on Wednesday, April 8, at the Sheldon Concert Hall.
- Two SLU Faculty Members Receive Emerson's Excellence in Teaching AwardTwo members of Saint Louis University's faculty have been recognized with Emerson's 2025 Excellence in Teaching Award. Sean Goretzke, M.D. (Neurology) and Melissa Ochoa, Ph.D. (Women's and Gender Studies) were both cited for their teaching prowess. The Emerson Excellence in Teaching Awards Program recognizes educators in the St. Louis metropolitan area annually for their leadership in and passion for teaching, their contributions to student learning, and their knowledge and creativity.
- Saint Louis University Launches Tuition Promise Covering Full Undergraduate Tuition for Eligible StudentsStarting in fall 2026, eligible first-time freshmen will be able to attend the University without paying undergraduate tuition through a new initiative aimed at expanding college access and affordability. The SLU Tuition Promise is for students from families with a combined Adjusted Gross Income of $60,000 or less and limited assets.
- SLU Chess Qualifies for Collegiate Chess ChampionshipSaint Louis University chess teams are heading to the Collegiate Chess Championship. The Billikens recently competed in the 2026 Pan-American Intercollegiate Chess Championship in Oak Brook, IL. SLU’s A Team finished fourth and secured a spot Collegiate Chess Championship finals, known as the President's Cup or colloquially as the “Final Four.” Additionally, the SLU B-Team was the top women’s squad at the tournament and will advance to the inaugural Women's President’s Cup.
- Building Connection and Collaboration: SLU President, Local Leaders Headline Leadership Speaker SeriesSaint Louis University’s Emerson Leadership Institute and Edward Jones Speaker Series will feature SLU President Edward Feser, Ph.D., as part of a joint speaker series on Wednesday, Jan. 21. Feser will speak on the theme, “Great Cities, Great Universities: Leading With Hope to Strengthen Our Shared Community,” sharing his vision for how SLU can lead boldly, collaborate meaningfully, and serve as an anchor of opportunity in St. Louis.
- SLU Hosting Journalists for 'Candid Conversations in Turbulent Times'The Saint Louis University American Studies Department will host award-winning ABC News anchor Linsey Davis and SLU alum John Krull (American Studies, '84) for the program "Candid Conversations in Turbulent Times." The event will take place at 6:30 p.m. on Thursday, Jan. 29, 2026, in the Anheuser Busch Auditorium in Cook Hall.
